The "One Big Beautiful Bill" Act included some changes to the way tips and overtime are taxed, and there are a lot of questions about it. CPA and TurboTax expert Lisa Greene-Lewis offers some clarity ...

Default rates rose on summer vintages, increasing net charge-offs to 45% of revenue (from 42%) and 59% of receivables (from 54%), a trend explicitly acknowledged by management. Management directly ...

As Benjamin Franklin once wrote, “in this world, nothing is certain but death and taxes.” And certainly, many Americans find themselves dreading both — the latter so much so that some may avoid filing ...

The key driver of our performance in the quarter was continued strength in our rental business, as the improvements we saw in the third quarter in the transmission and distribution markets continued ...

U.S. Tax Court Chief Judge Patrick Urda discusses the effects of the IRS’s staff changes and generative AI on the court and its continued evaluation of online access to documents.

Custom Truck One Source, Inc. ( CTOS) Q4 2025 Earnings Call March 10, 2026 9:00 AM EDT ...

Good morning, and welcome to Stagwell's Fourth Quarter and Full Year 2025 Earnings Webcast. My name is Ben Allanson, and I lead Investor Relations here at Stagwell. With me today are Mark Penn, ...

GAAP Net Income -- $110 million or $5.04 per share for the full year, reflecting a 175% increase. Adjusted Net Income -- $74 million or $3.04 per share for the full year, up $60 million, and a 429% ...

Q2 2026 Management View CEO Samuel Jonas highlighted strong overall results, attributing performance to top and bottom line expansion in NRS, BOSS Money, and net2phone. NRS recurring revenue increased ...

Stop paying cloud fees and secure client privacy today. The new UGREEN iDX NAS leverages a powerful local AI engine and offline LLM to organize your data.

New York City's new health commissioner, Alister Martin, MD, is stepping into the role at a time of growing tension between local public health officials and federal policy.

Skye Bioscience, Inc. (NASDAQ: SKYE) (“Skye” or the “Company”), a clinical stage biopharmaceutical company pioneering next-generation molecules that modulate G-protein-coupled receptors to treat ...